PhD Scientific Days 2022

Translational Medicine I. (Poster discussion will take place on the terrace of the room during the Coffee Break)

Development of LPA containing grafts for enhanced bone regeneration

Előadó neve

Dr. Majer, Aliz

Előadó munkahelye

Institute of Translational Medicine, Semmelweis University

Előadó telefonszáma

308295753

Előadó e-mail címe

majer.aliz@med.semmelweis-univ.hu

Az előadás címe

Development of LPA containing grafts for enhanced bone regeneration

Szerző(k) neve és munkahelye

Aliz Majer 1, Julianna Pesthy 1, Balázs Besztercei 1, Adél Hinsenkamp 1, Zsombor Lacza 2,3, Zoltán Benyó 1, *Éva Ruisanchez 1 and *István Hornyák 1
1 Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
2 OrthoSera GmbH, Krems an der Donau, Austria
3 Institute for Sports and Health Sciences, University of Physical Education, Budapest, Hungary
* These authors have contributed equally to this work.

Bemutatás módja

Szóbeli

Szekció

Translational Medicine I. (Poster discussion will take place on the terrace of the room during the Coffee Break)

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction: OrthoSera GmbH’s BoneAlbumin® product is an albumin-coated bone allograft which improves bone incorporation and remodelling. Lysophosphatidic acid (LPA) is a naturally occurring bioactive phospholipid which is present in the serum mainly bound to albumin. Osteoblast-produced LPA is present in bone tissue and under some pathophysiological conditions, such as fracture healing bone cells are exposed to high levels of platelet-derived LPA. In different bone cells LPA induces various cellular effects, including proliferation, differentiation, survival and migration. The proliferation, migration and differentiation of human bone marrow mesenchymal stem cells (MSCs) play a key role during the healing process.
Aims: We aimed to investigate the biocompatibility of LPA and determine the effect of different LPA species on the proliferation and migration of MSCs for product development.
Methods: MSCs were treated with either 18:1, 18:2 or 16:0 LPA (0.1-0.3-1-3-10 µM) alone or in combination with 4% human serum albumin (HSA) for 24 hours. After treatment the cell proliferation was measured using colorimetric XTT assay. The effect of 18:1, 18:2 and 16:0 LPA (1-3-10 µM) on the MSC migration was examined in wound healing assay. The HSA-LPA complex formation was investigated with Fourier-transform infrared (FTIR) spectroscopy.
Results: 18:1 LPA in 3 and 10 µM, 18:2 LPA in 1, 3 and 10 µM and 16:0 LPA in 0.3, 1, 3 and 10 µM doses significantly increased the MSCs proliferation compared to the control group, which effect was not observed when the LPA species were examined in the absence of HSA. In wound healing assay after 24 hours of LPA treatment no significant increase could be observed in the migration of the cells compared to the control group. The changes in the FTIR spectra of LPA-HSA compositions, compared to HSA alone, proved complex formation between the components.
Conclusion: Our experiments indicate that 18:1, 18:2 and 16:0 LPA species up to 10 µM dose have no cytotoxic effects. The different LPA species increase the proliferation of MSCs in dose-dependent manner when administered in the presence of HSA. These findings make the in vivo application of LPA-HSA complex promising in bone regeneration.
Funding: EFOP-3.6.3-VEKOP-16-2017-00009, TKP2021-EGA-25, 2020-1.1.6-JÖVŐ-2021-00010, KDP-2020 as well as OTKA K-125174, PD-132851, K-135683 and K-139230 grants.

University and Doctoral School

Semmelweis University, Doctoral School of Theoretical and Translational Medicine

Supervisor

Éva Ruisanchez and István Hornyák

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6946

Start

11:30

End

11:45

Authors (legacy)

Aliz Majer 1, Julianna Pesthy 1, Balázs Besztercei 1, Adél Hinsenkamp 1, Zsombor Lacza 2,3, Zoltán Benyó 1, *Éva Ruisanchez 1 and *István Hornyák 1
1 Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
2 OrthoSera GmbH, Krems an der Donau, Austria
3 Institute for Sports and Health Sciences, University of Physical Education, Budapest, Hungary
* These authors have contributed equally to this work.